The Agilent Cary 630 FTIR Spectrometer Quickly Identifies and Qualifies Pharmaceuticals

Agilent Cary 630 FTIR: Rapid Identification and Qualification of Pharmaceutical Materials — Summary

Significance of the topic

The reliable identification and qualification of raw materials, in-process intermediates, and finished products are central to pharmaceutical quality control and assurance. Globalized supply chains increase the risk of contaminated, counterfeit, or mislabelled ingredients entering manufacturing. Rapid, nondestructive analytical methods that deliver high sensitivity and reproducibility at checkpoints can prevent costly production failures and protect patient safety. Mid-infrared spectroscopy, and in particular attenuated total reflectance Fourier-transform infrared (ATR-FTIR), provides a fast, low‑maintenance approach well suited for routine screening and material qualification in regulated environments.

Objectives and study overview

This application study evaluates the Agilent Cary 630 FTIR spectrometer combined with Agilent MicroLab software and a chemometric classification method (partial least squares–discriminant analysis, PLS-DA) to:

• Differentiate pure active pharmaceutical ingredient (acetylsalicylic acid, ASA) from ASA intentionally contaminated with common excipients.
• Assess sensitivity and specificity compared with simple library-search identification.
• Demonstrate workflow integration and visual reporting for QA/QC use.

The aim was to detect low-level contamination (down to 0.5 % w/w) and produce a method suitable for routine qualification of incoming raw materials.

Methodology and experimental design

• Samples and design: Two batches of >99 % acetylsalicylic acid (ASA) from the same vendor were used. One batch was spiked separately with three common excipients—corn starch, microcrystalline cellulose (MCC), and lactose monohydrate—across approximately 1–20 % w/w to produce calibration and validation standards. Calibration sets included multiple spectra per class (14 spectra for pure ASA; 18, 13, and 19 spectra for ASA + corn starch, MCC, and lactose, respectively). Validation standards also included materials not present in the calibration (magnesium stearate, methylcellulose, calcium carbonate, and salicylic acid) to test specificity.
• Spectroscopy: Measurements were performed on an Agilent Cary 630 FTIR using a single‑bounce diamond ATR accessory with no sample grinding or solvent extraction. Spectra were recorded from 4000 to 650 cm−1, co‑adding 74 scans at 4 cm−1 resolution. Typical acquisition time per spectrum was ~30 seconds.
• Preprocessing and chemometrics: Spectra were mean-centered and processed with a nine‑point Savitzky–Golay first derivative before multivariate analysis. PLS‑DA (supervised classification) models were built to discriminate pure ASA from each excipient‑contaminated class. Separate PLS‑DA models were developed for each excipient class to improve sensitivity at low contamination levels. Models were combined within MicroLab using logic rules to produce a single decision workflow.

Used instrumentation

• Agilent Cary 630 FTIR spectrometer — compact, high‑performance FTIR meeting pharmacopoeial specifications for accuracy and resolution.
• Single‑bounce diamond ATR sampling accessory — robust, abrasion‑resistant ATR crystal suited to small sample volumes and rapid cleaning, recommended by USP for pharmaceutical solids.
• Agilent MicroLab software — method‑driven platform supporting PLS‑DA, logic-based result reporting, 21 CFR Part 11 data controls, and Auto IQ/OQ routines for qualification.

Key results and discussion >

• Model building: PLS‑DA models required different numbers of latent variables to obtain clear separation of pure ASA vs. each contaminated class: five factors for cornstarch, six for microcrystalline cellulose, and five for lactose monohydrate.
• Separation and thresholding: PLS regression outputs produced distinct class groupings. Arbitrary numeric labels were assigned to classes (e.g., 10 for pure, 20 for contaminated) and a threshold along the PLS‑DA axis was chosen from the score distributions for automated classification within MicroLab.
• Validation and performance: The combined logic method correctly classified 100 % of the tested validation samples in this study, distinguishing pure ASA from samples containing excipients at levels as low as 0.5 % w/w. The method also produced intuitive visual pass/fail reporting (green for pass, red for fail) in the MicroLab user interface.
• Robustness considerations: The authors emphasize that representative calibration sets should capture typical material variability (multiple vendors, batches, and processing differences) to ensure real‑world robustness of PLS‑DA classifiers.

Summary of figures and visual outputs

• PLS‑DA score plots illustrated clear two‑group separation between pure ASA and each excipient‑contaminated class, supporting the selection of classification thresholds.
• MicroLab logic configuration screenshots show how separate PLS‑DA models were combined into a single decision method with conditional reporting.
• Result screen visuals demonstrate straightforward pass/fail outputs suitable for QA operators, with color coding and simple flags for acceptance.

Benefits and practical applications of the method >

• Speed and simplicity: ATR‑FTIR measurement requires minimal sample preparation and delivers high‑quality spectra in ~30 seconds, enabling rapid screening of incoming materials.
• Non‑destructive and low sample consumption: Single‑bounce diamond ATR requires small sample amounts and is easy to clean between runs.
• Regulatory readiness: The Cary 630 meets major pharmacopoeial specifications; MicroLab supports 21 CFR Part 11 features and Auto IQ/OQ for instrument qualification.
• High sensitivity and specificity: PLS‑DA combined with appropriate preprocessing detects low‑level contamination not easily resolved by library search alone, making it suitable for qualification and release decisions.
• Operational integration: Visual pass/fail reporting and logic rules reduce user training needs and minimize risk of operator error in routine QC.

Future trends and potential applications

• Broader chemometric model libraries: Expanding representative calibration sets across suppliers, polymorphs, and process variabilities will improve generalizability and reduce false class assignments.
• Advanced machine learning: Incorporation of more robust classification algorithms (ensemble methods, support vector machines, convolutional neural networks for spectral features) and domain‑adaptation approaches can enhance performance on complex mixtures.
• On‑instrument deployable models: Edge‑deployed, validated models embedded in instrument software will accelerate point‑of‑use decisions in manufacturing and at receiving docks.
• Complementary modalities: Integration with Raman, NIR, or hyphenated techniques can improve sensitivity for compounds with weak IR signatures or to resolve structurally similar impurities.
• Regulatory and industry adoption: Harmonization of chemometric validation protocols and increased pharmacopeial guidance on multivariate methods will facilitate broader acceptance for release testing.

Conclusions

The study demonstrates that the Agilent Cary 630 FTIR, combined with single‑bounce diamond ATR and PLS‑DA implemented in Agilent MicroLab software, provides a fast, sensitive, and user‑friendly approach for the identification and qualification of pharmaceutical raw materials. The method reliably discriminated pure acetylsalicylic acid from samples containing common excipients down to about 0.5 % w/w in the tested sets, and the MicroLab logic and reporting features enable clear pass/fail decisions appropriate for QA/QC operations. With proper calibration design capturing expected material variability, ATR‑FTIR with supervised chemometrics is a practical tool for preventing out‑of‑specification materials from entering production.

References

1. F. Higgins, J. Seelenbinder. Cary 630 FTIR Pharmacopoeia compliance; Application Note, Agilent Technologies, Inc. Publication No. 5990-9379EN, 2011.
2. W. Dziki; J. Doddi. Pharmaceutical applications of mid-infrared spectroscopy in GMP compliance. Journal of GXP Compliance 2008, 12, 48-55.
3. F. H. Long. Spectroscopic qualitative analysis methods for pharmaceutical development and manufacturing. American Pharmaceutical Review 2011, 14.
4. F. Higgins; J. Seelenbinder. Quantitative measurement of active pharmaceutical ingredients using the diffuse reflectance Cary 630 FTIR; Application Note, Agilent Technologies, Inc. Publication No. 5990-9414EN, 2011.